MedTrace Logo

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

NCT03507686 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2024-02-23

Study results available
· View outcomes & findings →

Summary

The objective of the study is to evaluate the safety of bilateral, sequential sub-retinal administration of a single dose of BIIB111 in adult male participants with Choroideremia (CHM).

Conditions

  • Choroideremia

Interventions

DRUG

BIIB111

Administered as specified in the treatment arm.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-29
Primary Completion
2022-06-29
Completion
2022-06-29
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03507686 on ClinicalTrials.gov